This topic contains a solution. Click here to go to the answer

Author Question: A nurse is teaching a clientwho has uncontrolled asthma about the addition of two new medications. ... (Read 26 times)

bio_gurl

  • Hero Member
  • *****
  • Posts: 524
A nurse is teaching a clientwho has uncontrolled asthma about the addition of two new medications. Cromolyn and montelukast (Singulair) have been added. The client asks why these medications were added. What is the nurse's best response?
 
  1. They are used as second-line drugs for the treatment of asthma.
  2. Both work together in a synergist approach.
  3. The prescriber is discontinuing the albuterol (Proventil) and ipratropium (Atrovent).
  4. The prescriber is trying something new.

Question 2

A client is prescribed montelukast (Singulair), a leukotriene modifier. Which best describes why this medication was added to the treatment of the client's asthma?
 
  1. The medication is used for the prophylaxis of asthma.
  2. The medication is important for an acute bronchospasm.
  3. The medication has serious adverse effects including immunosuppression.
  4. The medication should not have been added to the treatment.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

Briannahope

  • Sr. Member
  • ****
  • Posts: 364
Answer to Question 1

1

Rationale 1: Leukotriene modifiers and mast cell stabilizers are added as second-line drugs for the treatment of asthma.
Rationale 2: These drugs do not work synergistically.
Rationale 3: The medications were added and there was no indication that the other medications would be discontinued.
Rationale 4: These medications are often added as second-line drugs.

Global Rationale: The mast cell stabilizers and leukotriene modifiers are second-line drugs for the treatment of asthma. These drugs are prescribed when bronchodilators and corticosteroids are unable to control asthma symptoms.

Answer to Question 2

1

Rationale 1: Leukotriene modifiers are added to reduce inflammation and ease bronchoconstriction by modifying the action of the leukotrienes, which are mediators of the inflammatory response.
Rationale 2: Leukotriene modifiers are not used in an acute bronchospasm.
Rationale 3: Leukotriene modifiers have adverse effects of headache, cough, nasal congestion, GI upset, and psychiatric effects such as depression and suicidal thinking.
Rationale 4: Leukotriene modifiers are added for the treatment of asthma that cannot be controlled by bronchodilators and corticosteroids.

Global Rationale: Leukotriene modifiers are added to the treatment of asthma when bronchodilators and corticosteroids are unable to. Leukotriene modifiers are added to reduce inflammation and ease bronchoconstriction by modifying the action of the leukotrienes, which are mediators of the inflammatory response. Leukotriene modifiers have adverse effects of headache, cough, nasal congestion, GI upset, and psychiatric effects such as depression and suicidal thinking.





 

Did you know?

More than nineteen million Americans carry the factor V gene that causes blood clots, pulmonary embolism, and heart disease.

Did you know?

Women are 50% to 75% more likely than men to experience an adverse drug reaction.

Did you know?

The average older adult in the United States takes five prescription drugs per day. Half of these drugs contain a sedative. Alcohol should therefore be avoided by most senior citizens because of the dangerous interactions between alcohol and sedatives.

Did you know?

In inpatient settings, adverse drug events account for an estimated one in three of all hospital adverse events. They affect approximately 2 million hospital stays every year, and prolong hospital stays by between one and five days.

Did you know?

In 2006, a generic antinausea drug named ondansetron was approved. It is used to stop nausea and vomiting associated with surgery, chemotherapy, and radiation therapy.

For a complete list of videos, visit our video library